Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2101
Thu, 16.09.2021
aap Implantate AG
aap Implantate AG ("aap" or the "Company") announces that the EBITDA guidance for the financial year 2021 is increased significantly by approx. 64% up to approx. 80% to a range between EUR -2.0 million and EUR -0.7 million. This is due to lower overall operating expenses, which will be incurred to a substantially lower extent as a result of strict [ … ]
Fri, 13.08.2021
aap Implantate AG
aap Implantate AG ("aap" or the "Company") remains on growth track with significant double-digit sales increases in the second quarter and first half of 2021 and achieved positive EBITDA in both reporting periods for the first time since focusing on trauma in 2016. aap increased sales by a significant 74% and 37% year-on-year in the second quarter [ … ]
Tue, 27.07.2021
aap Implantate AG
aap Implantate AG ("aap" or the "Company") recorded significant sales growth in both the second quarter and the first half of 2021. According to preliminary figures, aap increased sales in the second quarter of 2021 by a noticeable 74% year-on-year to EUR 3.3 million (Q2/2020: EUR 1.9 million). In the first six months of the current financial year, [ … ]
Fri, 18.06.2021
aap Implantate AG
aap Implantate AG ("aap") announces that as part of a non-commercial study (so-called IIT study; IIT = Investigator Initiated Trial) at University Hospital Regensburg, an implant coated with the Company's innovative antibacterial silver technology has been implanted in a patient for the first time ever. The implantation is part of a clinical study [ … ]
Fri, 28.05.2021
aap Implantate AG
aap Implantate AG ("aap" or "Company") has successfully started the financial year 2021 with sales growth and a significant improvement in earnings. Although the first quarter continued to be impacted by the still rampant COVID-19 pandemic, aap increased sales by 9% year-on-year to EUR 2.7 million (Q1/2020: EUR 2.5 million). Considering constant ex [ … ]
Wed, 19.05.2021
aap Implantate AG
aap Implantate AG ("aap" or "Company") achieved EBITDA of EUR -0.2 million in Q1/2021, significantly above the level in the corresponding period of the previous year (Q1/2020: EUR -2.2 million). Excluding one-time effects, recurring EBITDA in the first quarter of 2021 also improved noticeably year-on-year to EUR -0.2 million (Q1/2020: EUR -1.4 mill [ … ]
Fri, 30.04.2021
aap Implantate AG
aap Implantate AG ("aap" or the "Company") achieved sales of EUR 9.3 million (FY/2019: EUR 11.7 million) in a financial year 2020 marked by COVID-19 and thus a figure in the upper half of the guidance of EUR 8.0 million to EUR 10.0 million. Furthermore, despite COVID-19 and extensive restructuring expenses, the Company realized an improved EBITDA o [ … ]
Thu, 29.04.2021
aap Implantate AG
aap Implantate AG ("aap" or "Company") was informed at today's balance sheet meeting that the auditor Mazars GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Hamburg, will refuse the audit opinions for the annual financial report 2020 (HGB) and the consolidated annual financial report 2020 (IFRS). The background to thi [ … ]
Mon, 26.04.2021
aap Implantate AG
aap Implantate AG ("aap" or the "Company") has started the financial year 2021 with good sales growth. Although the first quarter was still strongly impacted by the still rampant COVID 19 pandemic, aap increased sales by 9% year-on-year to EUR 2.7 million (Q1/2020: EUR 2.5 million) according to preliminary figures. Taking into account constant exch [ … ]
Thu, 21.01.2021
aap Implantate AG
- Sales of EUR 9.3 million in a COVID-19-driven FY/2020 in upper half of guidance of EUR 8.0 to 10.0 million (FY/2019: EUR 11.7 million)
- Q4/2020 sales at EUR 2.4 million (Q4/2019: EUR 3.1 million); all markets except USA again strongly impacted by comprehensive lockdown measures in context of COVID-19 pandemic
- USA: Continued dynamic sales gro [ … ]